Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Posts Q4 Revenue Surge; R&D and Net Loss Grows

NEW YORK, Feb. 12 (GenomeWeb News) - Genaissance today posted a strong jump in fourth-quarter revenues atop increased R&D spending and a widened net loss.


Receipts for the three-month period ended Dec. 31 surged to $4.7 million from $2.6 million one year ago.


R&D spending, meantime, also increased in the fourth quarter to $6 million from $4.3 million in the year-ago period.


Net loss widened to $6.5 million, or $.28 per share, from $5.4 million, or $.24 per share, year over year, Genaissance said.


The company said it had around $16.8 million in cash, cash equivalents, and marketable securities as of Dec. 31.


Click here for more information.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.